'Regado' Nuff Money Now? IPO Brings $43M to Push Phase III
By Randy Osborne
Friday, August 23, 2013
Regado Biosciences Inc.'s initial public offering (IPO) may not have made quite the splash that others have made in recent months, but the sale of about 10.7 million shares at $4 each provided $43 million that will help the firm's REG1, on the runway for Phase III trials, move ahead in percutaneous coronary intervention for acute coronary syndrome.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.